Haisco Pharmaceutical Group Co., Ltd (SHE: 002653), a leading pharmaceutical company based in China, has announced that it has secured another clinical trial approval from the National Medical Products Administration (NMPA) for its investigational drug HSK42360. This BRAF V600 inhibitor is now poised to be evaluated in clinical trials for the treatment of BRAF V600 mutant advanced solid tumors.
Preclinical studies have demonstrated that HSK42360 not only shows remarkable anti-tumor efficacy across a variety of BRAF V600 mutated solid tumor models but also presents a favorable tolerability and safety profile, setting the stage for its potential impact on cancer treatment.- Flcube.com
